Health-care companies fell, but not by as much as the broad market, amid continued enthuasism for weight-loss drugs.

Gilead shares rallied after analysts at brokerage Jefferies said the biotech company will likely soon surprise investors with data from a clinical trial of an under-the-radar obesity drug.

Shares of incumbent obesity drug makers Novo Nordisk and Eli Lilly were more or less flat on the session.

Write to Rob Curran at

(END) Dow Jones Newswires

06-14-24 1727ET